Defactinib

Target: This ligand targets focal adhesion kinase PTK2/FAK and proline-rich tyrosine kinase PTK2B/PYK2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for focal adhesion kinase PTK2/FAK and proline-rich tyrosine kinase PTK2B/PYK2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings focal adhesion kinase PTK2/FAK into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Targeted FAK Degradation: Defactinib can be incorporated as a kinase-binding ligand within PROTAC designs to recruit an E3 ligase and drive selective degradation of FAK (PTK2). This enables functional dissection of FAK signaling beyond catalytic inhibition, supporting studies on pathway rewiring, adhesion dynamics, and downstream transcriptional outputs.

• Investigate Adhesion Signaling Networks: Using Defactinib-based PROTACs allows researchers to degrade FAK in controlled cellular contexts and compare phenotypes with conventional kinase blockade. Such approaches help clarify how FAK turnover influences focal adhesion assembly, mechanotransduction, and migration, providing mechanistic insight into resistance mechanisms and compensatory signaling.

• Map Kinase-Dependent Degradation Specificity: Defactinib-derived ligands can be used to evaluate degradation selectivity across related kinases and FAK family members. By systematically varying linker length and E3 ligase recruitment, researchers can determine whether observed effects arise from FAK degradation or off-target engagement, refining target attribution in targeted protein degradation experiments.

• Study Resistance to FAK Inhibition: Defactinib PROTAC strategies can be applied to test whether degrading FAK yields more durable pathway suppression than inhibitor treatment. This supports investigation of resistance states where kinase activity persists or signaling reactivates, enabling exploration of degradation-driven changes in survival signaling and phenotypic plasticity.

Defactinib is a FAK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Defactinib is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.